Mesothelioma is a rare but deadly form of cancer: the five-year survival rate for patients diagnosed with the disease is between five and ten percent. Although aggressive surgery can help some patients with early-stage mesothelioma, ...
Feb 29, 2016
0
336
It's been called the "fifth pillar" of cancer treatment: genetically re-engineering the human immune system to recognize cancers and fight them.
Nov 6, 2014
0
0
Scientists have found that individuals who carry a mutation in a gene called BAP1 are susceptible to developing two forms of cancer – mesothelioma, and melanoma of the eye. Additionally, when these individuals are exposed ...
Aug 28, 2011
0
0
As school buses drive down the gravel roads in Dunn County, North Dakota, they stir up more than dirt. The clouds of dust left in their wake contain such high levels of the mineral erionite that those who breathe in the air ...
Jul 25, 2011
4
0
The nuclear protein Ki67 is a meaningful biomarker for tumor aggressiveness and for the success of surgical therapy in pleural mesothelioma, a malignant disease of the pleura. This is the clear and promising result of an ...
Jun 26, 2024
0
0
Pleural mesothelioma (PM) is mainly caused by asbestos exposure and characterized by poor prognosis and limited therapeutic options. A recent research study led by Karin Schelch and Michael Grusch from MedUni Vienna identified ...
Oct 11, 2023
0
2
A model developed by the International Association for the Study of Lung Cancer in 2009 to help better stage mesothelioma cases performed well, according to an independent analysis presented at The International Association ...
Sep 12, 2023
0
0
Extended pleurectomy decortication combined with chemotherapy is associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life compared to platinum and pemetrexed ...
Sep 11, 2023
0
5
Identifying and analyzing volatile organic compounds in exhaled breath of patients with malignant pleural mesothelioma showed promise as a screening method for MPM, according to research presented today at the International ...
Sep 9, 2023
0
16
Peter Szlosarek, Professor of Medical Oncology at Queen Mary's Barts Cancer Institute, presented his team's results from the ATOMIC-Meso clinical trial in partnership with Polaris Pharmaceuticals, Inc., at the American Association ...
Apr 18, 2023
0
15
